GoodRx director Dipanjan Deb resigns from board

GoodRx Holdings, Inc. reported that board member Dipanjan Deb resigned from its Board of Directors, effective February 26, 2026.

Rhea-AI Filing Summary

GoodRx Holdings, Inc. reported that board member Dipanjan Deb resigned from its Board of Directors, effective February 26, 2026. The company states that Mr. Deb’s decision to step down was not due to any disagreement with GoodRx or its management regarding operations, policies, or practices.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GoodRx (GDRX) disclose in this 8-K filing?

GoodRx disclosed that director Dipanjan Deb resigned from its Board of Directors effective February 26, 2026. The company noted his departure was not due to any disagreement with management or policies, indicating a routine governance change rather than a conflict-driven exit.

When did GoodRx director Dipanjan Deb resign from the board?

Dipanjan Deb resigned from the GoodRx Board of Directors effective February 26, 2026. The company reported the decision and emphasized that his resignation was not related to disagreements over operations, policies, or practices at GoodRx Holdings, Inc.

Did GoodRx say there was any disagreement behind Dipanjan Deb’s resignation?

GoodRx stated that Dipanjan Deb’s decision to resign from its Board of Directors was not the result of any disagreement. This includes no disputes with the company or its management regarding GoodRx’s operations, policies, or business practices, suggesting an amicable departure.

Which board member resigned from GoodRx (GDRX) according to the 8-K?

Board member Dipanjan Deb resigned from GoodRx Holdings, Inc.’s Board of Directors. His resignation was effective February 26, 2026, and the company specifically noted that it did not arise from any disagreement with GoodRx’s management or corporate policies.

Who signed the GoodRx 8-K reporting the director resignation?

The 8-K reporting Dipanjan Deb’s resignation was signed by Christopher McGinnis. He signed in his capacity as GoodRx Holdings, Inc.’s Chief Financial Officer and Treasurer, acting as the duly authorized officer for this current report on Form 8-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:31 PM EST Learn about SEC filing dates

0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 26, 2026

________________________________________

GoodRx Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)

________________________________________

Delaware	001-39549	47-5104396
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2701 Olympic Boulevard
Santa Monica, California		90404
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (855) 268-2822

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the

registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		GDRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act

of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Compensatory Arrangements of Certain Officers.

Departure of Director

On February 26, 2026, Dipanjan Deb notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a

member of the Company’s Board of Directors, effective as of February 26, 2026. Mr. Deb has indicated to the Company that

his decision to resign is not the result of any disagreement with the Company or its management on any matter relating to

the Company’s operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report

to be signed on its behalf by the undersigned hereunto duly authorized.

			GOODRX HOLDINGS, INC.
Date:	February 27, 2026	By:	/s/ Christopher McGinnis
			Name: Christopher McGinnis Title: Chief Financial Officer & Treasurer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB